Merus N.V. is sponsoring the ongoing study, which continues to recruit patients worldwide. Zenocutuzumab is a first-in-class, humanized, full-length immunoglobulin G1 bispecific antibody that targets ...

Akeso is dedicated to transforming the global oncology treatment landscape by establishing new standards of care for cancer patients worldwide. A key element of this mission is the company's "IO 2.0 + ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Zenocutuzumab (Bizengri), a bispecific antibody against HER2 and HER3, showed efficacy in patients with advanced NRG1 ...

The HER2 asset, known as both RG6194 and runimotamab ... Roche also included RG7827, a 4-1BBxFAP bispecific antibody, on the list of the candidates removed from its phase 1 pipeline.

JSKN003 is an anti-HER2 bispecific ADC developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. The antibody molecule KN026 is site-specifically modified via enzyme ...

JSKN003 is an anti-HER2 bispecific ADC developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. The antibody molecule KN026 is site-specifically modified via enzyme ...

Innovative Bispecific Antibody Therapies in Cancer Treatment Emerge as Patent Filings SurgeDublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody & Cancer Patent Landscape Analysis" report ...

a HER2-targeted antibody that disrupts receptor heterodimerization between EGFR/HER2 and HER2/HER3; CP-751871, an IGF1R-targeted antibody; the IGF1R kinase inhibitor NVP-AEW541; and the mammalian ...